{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T17:45:01Z","timestamp":1771263901129,"version":"3.50.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2016,3,2]],"date-time":"2016-03-02T00:00:00Z","timestamp":1456876800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1007\/s10557-016-6655-4","type":"journal-article","created":{"date-parts":[[2016,3,2]],"date-time":"2016-03-02T01:00:40Z","timestamp":1456880440000},"page":"297-304","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Clinical Profile of Statin Intolerance in the Phase 3 GAUSS-2 Study"],"prefix":"10.1007","volume":"30","author":[{"given":"Leslie","family":"Cho","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Rocco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Colquhoun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert S.","family":"Rosenson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo","family":"Dent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allen","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rob","family":"Scott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott M.","family":"Wasserman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik","family":"Stroes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,3,2]]},"reference":[{"key":"6655_CR1","unstructured":"National Center for Health Statistics. Health, United States, 2010: with special feature on death and dying. Hyattsville, MD. 2011."},{"key":"6655_CR2","doi-asserted-by":"crossref","first-page":"75","DOI":"10.7326\/0003-4819-159-1-201307020-00022","volume":"159","author":"H Zhang","year":"2013","unstructured":"Zhang H, Plutzky J, Turchin A. Discontinuation of statins in routine care settings. Ann Intern Med. 2013;159:75\u20136.","journal-title":"Ann Intern Med"},{"key":"6655_CR3","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.jacc.2013.03.030","volume":"62","author":"PD Thompson","year":"2013","unstructured":"Thompson PD, Parker B. Statins, exercise, and exercise training. J Am Coll Cardiol. 2013;62:715\u20136.","journal-title":"J Am Coll Cardiol"},{"key":"6655_CR4","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3949\/ccjm.78a.10073","volume":"78","author":"G Fernandez","year":"2011","unstructured":"Fernandez G, Spatz ES, Jablecki C, Phillips PS. Statin myopathy: a common dilemma not reflected in clinical trials. Cleve Clin J Med. 2011;78:393\u2013403.","journal-title":"Cleve Clin J Med"},{"key":"6655_CR5","doi-asserted-by":"crossref","first-page":"6C","DOI":"10.1016\/j.amjcard.2005.12.006","volume":"97","author":"H Bays","year":"2006","unstructured":"Bays H. Statin safety: an overview and assessment of the data--2005. Am J Cardiol. 2006;97:6C\u201326.","journal-title":"Am J Cardiol"},{"key":"6655_CR6","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.ahj.2013.06.004","volume":"166","author":"WM Mampuya","year":"2013","unstructured":"Mampuya WM, Frid D, Rocco M, et al. Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience. Am Heart J. 2013;166:597\u2013603.","journal-title":"Am Heart J"},{"key":"6655_CR7","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1093\/eurheartj\/eht295","volume":"34","author":"R Chowdhury","year":"2013","unstructured":"Chowdhury R, Khan H, Heydon E, et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J. 2013;34:2940\u20138.","journal-title":"Eur Heart J"},{"key":"6655_CR8","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1056\/NEJMoa1315665","volume":"370","author":"MJ Pencina","year":"2014","unstructured":"Pencina MJ, Navar-Boggan AM, D\u2019Agostino Sr RB, et al. Application of new cholesterol guidelines to a population-based sample. N Engl J Med. 2014;370:1422\u201331.","journal-title":"N Engl J Med"},{"key":"6655_CR9","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.jacl.2014.03.004","volume":"8","author":"RS Rosenson","year":"2014","unstructured":"Rosenson RS, Baker SK, Jacobson TA, Kopecky SL, Parker BA. The National Lipid Association\u2019s Muscle Safety Expert P. An assessment by the Statin Muscle Safety Task Force: 2014 update. J Clin Lipidol. 2014;8:S58\u201371.","journal-title":"J Clin Lipidol"},{"key":"6655_CR10","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.cjca.2013.09.023","volume":"29","author":"GB Mancini","year":"2013","unstructured":"Mancini GB, Tashakkor AY, Baker S, et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Working Group Consensus update. Can J Cardiol. 2013;29:1553\u201368.","journal-title":"Can J Cardiol"},{"key":"6655_CR11","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1161\/CIRCOUTCOMES.111.000071","volume":"6","author":"H Naci","year":"2013","unstructured":"Naci H, Brugts J, Ades T. Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246 955 participants from 135 randomized, controlled trials. Circ Cardiovasc Qual Outcomes. 2013;6:390\u20139.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"6655_CR12","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","volume":"360","author":"Heart Protection Study Collaborative G","year":"2002","unstructured":"Heart Protection Study Collaborative G. MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7\u201322.","journal-title":"Lancet"},{"key":"6655_CR13","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/S0140-6736(02)11600-X","volume":"360","author":"J Shepherd","year":"2002","unstructured":"Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360:1623\u201330.","journal-title":"Lancet"},{"key":"6655_CR14","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1001\/jama.1990.03450090041020","volume":"264","author":"DM Black","year":"1990","unstructured":"Black DM, Lamkin G, Olivera EH, Laskarzewski PM, Stein EA. Sleep disturbance and HMG CoA reductase inhibitors. JAMA. 1990;264:1105.","journal-title":"JAMA"},{"key":"6655_CR15","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1592\/phco.29.7.800","volume":"29","author":"MA Evans","year":"2009","unstructured":"Evans MA, Golomb BA. Statin-associated adverse cognitive effects: survey results from 171 patients. Pharmacotherapy. 2009;29:800\u201311.","journal-title":"Pharmacotherapy"},{"key":"6655_CR16","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.amjmed.2004.07.041","volume":"117","author":"MF Muldoon","year":"2004","unstructured":"Muldoon MF, Ryan CM, Sereika SM, Flory JD, Manuck SB. Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults. Am J Med. 2004;117:823\u20139.","journal-title":"Am J Med"},{"key":"6655_CR17","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/clpt.1991.213","volume":"50","author":"AN Vgontzas","year":"1991","unstructured":"Vgontzas AN, Kales A, Bixler EO, Manfredi RL, Tyson KL. Effects of lovastatin and pravastatin on sleep efficiency and sleep stages. Clin Pharmacol Ther. 1991;50:730\u20137.","journal-title":"Clin Pharmacol Ther"},{"key":"6655_CR18","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1592\/phco.23.7.871.32720","volume":"23","author":"LR Wagstaff","year":"2003","unstructured":"Wagstaff LR, Mitton MW, Arvik BM, Doraiswamy PM. Statin-associated memory loss: analysis of 60 case reports and review of the literature. Pharmacotherapy. 2003;23:871\u201380.","journal-title":"Pharmacotherapy"},{"key":"6655_CR19","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1016\/j.jacc.2014.03.019","volume":"63","author":"E Stroes","year":"2014","unstructured":"Stroes E, Colquhoun D, Sullivan D, et al. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance. J Am Coll Cardiol. 2014;63:2541\u20138.","journal-title":"J Am Coll Cardiol"},{"key":"6655_CR20","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/clc.22248","volume":"37","author":"L Cho","year":"2014","unstructured":"Cho L, Rocco M, Colquhoun D, et al. Design and rationale of the GAUSS-2 study trial: a double-blind, ezetimibe-controlled phase 3 study of the efficacy and tolerability of evolocumab (AMG 145) in subjects with hypercholesterolemia who are intolerant of statin therapy. Clin Cardiol. 2014;37:131\u20139.","journal-title":"Clin Cardiol"},{"key":"6655_CR21","doi-asserted-by":"crossref","unstructured":"National Cholesterol Education Program Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143\u2013421.","DOI":"10.1161\/circ.106.25.3143"},{"key":"6655_CR22","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/S0140-6736(07)60716-8","volume":"370","author":"J Armitage","year":"2007","unstructured":"Armitage J. The safety of statins in clinical practice. Lancet. 2007;370:1781\u201390.","journal-title":"Lancet"},{"key":"6655_CR23","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ahj.2014.03.019","volume":"168","author":"HV Ganga","year":"2014","unstructured":"Ganga HV, Slim HB, Thompson PD. A systematic review of statin-induced muscle problems in clinical trials. Am Heart J. 2014;168:6\u201315.","journal-title":"Am Heart J"},{"key":"6655_CR24","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1001\/jama.2015.1335","volume":"313","author":"CB Newman","year":"2015","unstructured":"Newman CB, Tobert JA. Statin intolerance: reconciling clinical trials and clinical experience. JAMA. 2015;313:1011\u20132.","journal-title":"JAMA"},{"key":"6655_CR25","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S0735-1097(02)02030-2","volume":"40","author":"RC Pasternak","year":"2002","unstructured":"Pasternak RC, Smith Jr SC, Bairey-Merz CN, et al. ACC\/AHA\/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol. 2002;40:567\u201372.","journal-title":"J Am Coll Cardiol"},{"key":"6655_CR26","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","volume":"36","author":"ES Stroes","year":"2015","unstructured":"Stroes ES, Thompson PD, Corsini A, et al. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J. 2015;36:1012\u201322.","journal-title":"Eur Heart J"},{"key":"6655_CR27","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","volume":"19","author":"E Bruckert","year":"2005","unstructured":"Bruckert E, Hayem G, Dejager S, Yau C, Begaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study. Cardiovasc Drugs Ther. 2005;19:403\u201314.","journal-title":"Cardiovasc Drugs Ther"},{"key":"6655_CR28","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jacl.2012.03.003","volume":"6","author":"JD Cohen","year":"2012","unstructured":"Cohen JD, Brinton EA, Ito MK, Jacobson TA. Understanding statin use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users. J Clin Lipidol. 2012;6:208\u201315.","journal-title":"J Clin Lipidol"},{"key":"6655_CR29","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1161\/CIRCULATIONAHA.112.136101","volume":"127","author":"BA Parker","year":"2013","unstructured":"Parker BA, Capizzi JA, Grimaldi AS, et al. Effect of statins on skeletal muscle function. Circulation. 2013;127:96\u2013103.","journal-title":"Circulation"},{"key":"6655_CR30","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jacc.2012.09.036","volume":"61","author":"S Larsen","year":"2013","unstructured":"Larsen S, Stride N, Hey-Mogensen M, et al. Simvastatin effects on skeletal muscle: relation to decreased mitochondrial function and glucose intolerance. J Am Coll Cardiol. 2013;61:44\u201353.","journal-title":"J Am Coll Cardiol"},{"issue":"supp 2","key":"6655_CR31","first-page":"2108","volume":"130","author":"PM Moriarty","year":"2014","unstructured":"Moriarty PM, Thompson PD, Cannon C, et al. ODYSSEY ALTERNATIVE: efficacy and safety of alirocumab versus ezetimibe, in patients with statin intolerance defined by placebo run-in and stain rechallenge arm. Circulation. 2014;130(supp 2):2108 [abstr].","journal-title":"Circulation"},{"key":"6655_CR32","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/art.30156","volume":"63","author":"AL Mammen","year":"2011","unstructured":"Mammen AL, Chung T, Christopher-Stine L, et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum. 2011;63:713\u201321.","journal-title":"Arthritis Rheum"},{"key":"6655_CR33","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000096","volume":"2","author":"S Ramanathan","year":"2015","unstructured":"Ramanathan S, Langguth D, Hardy TA, et al. Clinical course and treatment of anti-HMGCR antibody-associated necrotizing autoimmune myopathy. Neurol Neuroimmunol Neuroinflamm. 2015;2, e96.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"6655_CR34","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/sleep\/22.1.117","volume":"22","author":"BL Ehrenberg","year":"1999","unstructured":"Ehrenberg BL, Lamon-Fava S, Corbett KE, McNamara JR, Dallal GE, Schaefer EJ. Comparison of the effects of pravastatin and lovastatin on sleep disturbance in hypercholesterolemic subjects. Sleep. 1999;22:117\u201321.","journal-title":"Sleep"},{"key":"6655_CR35","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/MAJ.0b013e3181e15da8","volume":"340","author":"FS Rzouq","year":"2010","unstructured":"Rzouq FS, Volk ML, Hatoum HH, Talluri SK, Mummadi RR, Sood GK. Hepatotoxicity fears contribute to underutilization of statin medications by primary care physicians. Am J Med Sci. 2010;340:89\u201393.","journal-title":"Am J Med Sci"},{"key":"6655_CR36","first-page":"1180","volume":"172","author":"BA Golomb","year":"2012","unstructured":"Golomb BA, Evans MA, Dimsdale JE, White HL. Effects of statins on energy and fatigue with exertion: results from a randomized controlled trial. Arch Intern Med. 2012;172:1180\u20132.","journal-title":"Arch Intern Med"},{"key":"6655_CR37","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"2013","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington: American Psychiatric Association; 2013.","edition":"5"},{"key":"6655_CR38","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/1741-7015-10-154","volume":"10","author":"A O\u2019Neil","year":"2012","unstructured":"O\u2019Neil A, Sanna L, Redlich C, et al. The impact of statins on psychological wellbeing: a systematic review and meta-analysis. BMC Med. 2012;10:154.","journal-title":"BMC Med"},{"key":"6655_CR39","doi-asserted-by":"crossref","unstructured":"Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med. 1998;339:1349\u201357.","DOI":"10.1056\/NEJM199811053391902"},{"key":"6655_CR40","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1177\/2047487312445562","volume":"20","author":"MT Cooney","year":"2013","unstructured":"Cooney MT, Kotseva K, Dudina A, De Backer G, Wood D, Graham I. Determinants of risk factor control in subjects with coronary heart disease: a report from the EUROASPIRE III investigators. Eur J Prev Cardiol. 2013;20:686\u201391.","journal-title":"Eur J Prev Cardiol"},{"key":"6655_CR41","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1161\/CIRCULATIONAHA.108.190769","volume":"118","author":"JH Lichtman","year":"2008","unstructured":"Lichtman JH, Bigger Jr JT, Blumenthal JA, et al. Depression and coronary heart disease: recommendations for screening, referral, and treatment: a science advisory from the American Heart Association Prevention Committee of the Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Psychiatric Association. Circulation. 2008;118:1768\u201375.","journal-title":"Circulation"},{"key":"6655_CR42","doi-asserted-by":"crossref","first-page":"483","DOI":"10.5694\/mja13.10153","volume":"198","author":"DM Colquhoun","year":"2013","unstructured":"Colquhoun DM, Bunker SJ, Clarke DM, et al. Screening, referral and treatment for depression in patients with coronary heart disease. Med J Aust. 2013;198:483\u20134.","journal-title":"Med J Aust"},{"key":"6655_CR43","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1016\/j.ehj.2003.08.017","volume":"24","author":"RA Stewart","year":"2003","unstructured":"Stewart RA, North FM, West TM, et al. Depression and cardiovascular morbidity and mortality: cause or consequence? Eur Heart J. 2003;24:2027\u201337.","journal-title":"Eur Heart J"},{"key":"6655_CR44","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","volume":"279","author":"JR Downs","year":"1998","unstructured":"Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS\/TexCAPS. Air Force\/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279:1615\u201322.","journal-title":"JAMA"},{"key":"6655_CR45","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","volume":"333","author":"J Shepherd","year":"1995","unstructured":"Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:1301\u20137.","journal-title":"N Engl J Med"},{"key":"6655_CR46","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","volume":"361","author":"PS Sever","year":"2003","unstructured":"Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149\u201358.","journal-title":"Lancet"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-016-6655-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10557-016-6655-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-016-6655-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T00:56:34Z","timestamp":1567644994000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10557-016-6655-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,2]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["6655"],"URL":"https:\/\/doi.org\/10.1007\/s10557-016-6655-4","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,2]]}}}